Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis

NCT06127043 is registered in ClinicalTrials.gov with AnaptysBio, Inc. as lead sponsor.

NCT NCT06127043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06127043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis
Lead sponsor
AnaptysBio, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 4, 2023
Completion date
May 31, 2026
Enrollment
132 (estimated)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis